US 6,982,157 B1 | ||
Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methylsulfonyl)amino] pyrimidin-5-yl] (3r,5s) -3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3A4 | ||
John S Pears, Macclesfield (United Kingdom); Ali Raza, Wilmington, Del. (US); Howard G Hutchinson, Wilmington, Del. (US); Dennis Schneck, Wilmington, Del. (US); Takahiko Baba, Toyonaka (Japan); and Akira Touchi, Toyonaka (Japan) | ||
Assigned to AstraZeneca AB, London (United Kingdom); and Shionogi & Co., Ltd., Osaka (Japan) | ||
Appl. No. 9/889,414 PCT Filed Feb. 01, 2000, PCT No. PCT/GB00/00278 § 371(c)(1), (2), (4) Date Nov. 13, 2001, PCT Pub. No. WO00/45817, PCT Pub. Date Aug. 10, 2000. |
||
Claims priority of application No. 9902593 (GB), filed on Feb. 06, 1999; application No. 9921063 (GB), filed on Sep. 08, 1999; and application No. 9921064 (GB), filed on Sep. 08, 1999. | ||
Int. Cl. C12N 9/99 (2006.01) |
U.S. Cl. 435—184 | 4 Claims |
1. A non-interacting drug combination comprising a first drug, which is the HMG-CoA reductase inhibitor (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof, and a second drug, which is selected from the group consisting of bezafibrate, clofibrate, ciprofibrate, fenofibrate and niacin. |